{
    "id": "5c654c14e842deac67000025",
    "question": "Does lucatumumab bind to CD140?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the provided documents and look for information about lucatumumab. Unfortunately, none of the documents provide information about lucatumumab. However, we can try to make an educated guess by looking for any mention of a similar compound or a similar structure. We can also try to look for any patterns or keywords that might suggest the correct answer. One possible approach is to look for documents that discuss other monoclonal antibodies or immunotherapies, and see if any of them mention a compound called lucatumumab. After a thorough search, we found that there is no mention of lucatumumab in any of the provided documents. Therefore, based on the available information, we cannot determine if lucatumumab binds to CD140 or not.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_6170",
            "title": "Pharmacology_Katzung",
            "content": "Ofatumumab is a human IgG1 monoclonal antibody directed against an epitope on CD20 on lymphocytes. Rituximab, the first approved CD20 monoclonal antibody (see below), also binds CD20, but to a different epitope. Ofatumumab is approved for patients with CLL who are refractory to fludarabine and alemtuzumab. Ofatumumab binds to all B cells including B-CLL. It is thought to lyse B-CLL cells in the presence of complement and to mediate antibody-dependent cellular cytotoxicity. There is a slight risk of hepatitis B virus reactivation in patients taking ofatumumab."
        },
        {
            "id": "Pharmacology_Katzung_6000",
            "title": "Pharmacology_Katzung",
            "content": "Monoclonal antibody targeted therapies are being widely used in CLL, especially in relapsed or refractory disease. Rituximab is an anti-CD20 antibody that has documented clinical activity in this setting. This chimeric antibody appears to enhance the antitumor effects of cytotoxic chemotherapy and is also effective in settings in which resistance to chemotherapy has developed. Ofatumumab is a fully human IgG1 antibody that binds to a different CD20 epitope than rituximab. Of note, it maintains activity in rituximab-resistant tumors, and it is presently approved for CLL that is refractory to fludarabine and alemtuzumab therapy."
        },
        {
            "id": "InternalMed_Harrison_6415",
            "title": "InternalMed_Harrison",
            "content": "Another class of immunoregulatory antibody is the \u201cbispecific\u201d antibody blinatumomab, which was constructed to have an anti-CD19 antigen combining site as one valency of an antibody with anti-CD3 binding site as the other valency. This antibody thus can bring T cells (with its anti-CD3 activity) close to B cells bearing the CD19 determinant. Blinatumomab is active in B cell neoplasms such as acute lymphocytic leukemia, which may not have prominent expression of the CD20 targeted by rituximab."
        },
        {
            "id": "InternalMed_Harrison_22982",
            "title": "InternalMed_Harrison",
            "content": "Natalizumab is a recombinant humanized IgG4 antibody against \u03b14-integrin that has been shown to be effective in induction and maintenance of patients with CD. It has been approved since February 2008 for the treatment of patients with CD refractory or intolerant to anti-TNF therapy. The rates of response and remission at 3 months are about 60% and 40%, respectively, with a sustained remission rate of about 40% at 36 weeks."
        },
        {
            "id": "Pharmacology_Katzung_6177",
            "title": "Pharmacology_Katzung",
            "content": "Brentuximab vedotin is an antibody-drug conjugate that binds CD30, a cell surface marker in the TNF receptor superfamily that is expressed on anaplastic large T-cell lymphomas and on Reed-Sternberg cells in Hodgkin\u2019s lymphoma; it may also be expressed on activated leukocytes. Brentuximab vedotin consists of a chimeric (mouse-human) IgG1 linked to monomethylauristatin E (MMAE), a microtubule-disrupting agent that induces cell cycle arrest and apoptosis. When this ADC binds CD30 on the cell surface, the complex is internalized followed by proteolytic cleavage of MMAE from the IgG. Brentuximab is approved for treatment of patients with Hodgkin\u2019s lymphoma after failure of autologous stem cell transplantation or after failure of at least two previous chemotherapy regimens. It is also approved for patients with systemic anaplastic large cell lymphoma after failure of at least one previous multiagent chemotherapy regimen. Patients taking brentuximab vedotin should be monitored primarily for"
        },
        {
            "id": "Pharmacology_Katzung_6163",
            "title": "Pharmacology_Katzung",
            "content": "Daratumumab binds to CD38, which is over-expressed on myeloma cells. Binding of daratumumab to CD38 on myeloma cells likely induces cell death by apoptosis, complement-dependent cytotoxicity, or antibody-dependent cytotoxicity. It is approved by the FDA for use in multiple myeloma patients who are refractory to standard treatments, although phase III trials are ongoing regarding its use as a frontline therapy. Elotuzumab is FDA approved for the treatment of relapsed multiple myeloma. This Mab binds signaling lymphocytic activation molecule F7 (SLAMF7) on myeloma cells. It enables killing of multiple myeloma tumor cells by antibody-dependent cell-mediated cytotoxicity (ADCC)."
        },
        {
            "id": "Cell_Biology_Alberts_748",
            "title": "Cell_Biology_Alberts",
            "content": "C. Why is each successive peak in Figure Q3\u20132B a little higher than the one before? D. Why does the force collapse so abruptly after each peak? 3\u201312 Rous sarcoma virus (RSV) carries an oncogene called Src, which encodes a continuously active protein tyrosine kinase that leads to unchecked cell proliferation. Normally, Src carries an attached fatty acid (myristoylate) group that allows it to bind to the cytoplasmic side of the plasma membrane. A mutant version of Src that does not allow attachment of myristoylate does not bind to the membrane. Infection of cells with RSV encoding either the normal or the mutant form of Src leads to the same high level of protein tyrosine kinase activity, but the mutant Src does not cause cell proliferation. a."
        },
        {
            "id": "Pharmacology_Katzung_5980",
            "title": "Pharmacology_Katzung",
            "content": "Necitumumab is a fully human IgG1 monoclonal antibody directed against EGFR. Like cetuximab and panitumumab, it works through inhibition of the EGFR signaling pathway. However, as with cetuximab, necitumumab is of the G1 isotype, and as such, its antitumor activity may also be mediated, at least in part, through immunologically mediated mechanisms. It is approved for use in combination with gemcitabine and cisplatin chemotherapy for the treatment of squamous NSCLC. The main adverse effects are what have been previously described for other anti-EGFR antibodies, and both venothrombolic and arterioembolic events have also been described."
        },
        {
            "id": "Immunology_Janeway_4071",
            "title": "Immunology_Janeway",
            "content": "Another co-stimulatory pathway that has been targeted in psoriasis is the interaction between the adhesion molecule CD2 on T cells and CD58 (LFA-3) on antigen-presenting cells. A recombinant CD58\u2013IgG1 fusion protein, called alefacept (Amevive), inhibits the interaction between CD2 and CD58, and is now a routine and effective treatment for psoriasis. Although memory T cells are targeted by this therapy, responses to vaccination such as antitetanus remain intact. 16-11 Some commonly used drugs have immunomodulatory properties."
        },
        {
            "id": "InternalMed_Harrison_25249",
            "title": "InternalMed_Harrison",
            "content": "abatacept Abatacept is a soluble fusion protein consisting of the extracellular domain of human CTLA-4 linked to the modified portion of human IgG. It inhibits the co-stimulation of T cells by blocking CD28-CD80/86 interactions and may also inhibit the function of antigen-presenting cells by reverse signaling through CD80 and CD86. Abatacept has been shown in clinical trials to reduce disease activity, slow radiographic progression of damage, and improve functional disability. Many patients receive abatacept in combination with methotrexate or another DMARD such as leflunomide. Abatacept therapy has been associated with an increased risk of infection."
        },
        {
            "id": "Immunology_Janeway_4055",
            "title": "Immunology_Janeway",
            "content": "In addition to their use in preventing transplantation rejection, monoclonal antibodies can be used to treat certain autoimmune diseases, and the different immune mechanisms targeted are discussed in the next few sections. We start by discussing the use of depleting and nondepleting antibodies to remove lymphocytes nonspecifically. The anti-CD20 monoclonal antibody rituximab was originally developed to treat B-cell lymphomas, but has also been tried in treating certain autoimmune diseases. By ligating CD20, rituximab (Rituxan, MabThera) transduces a signal that induces lymphocyte apoptosis and depletes B cells for several months. Certain autoimmune diseases are believed to involve autoantibody-mediated pathogenesis. There is evidence for the efficacy of rituximab in some patients with autoimmune hemolytic anemia, SLE, rheumatoid arthritis, or type II mixed cryoglobulinemia, all of which have autoantibodies as a part of their clinical presentation. Although CD20 is not expressed on"
        },
        {
            "id": "InternalMed_Harrison_6409",
            "title": "InternalMed_Harrison",
            "content": "also regulates macrophage function, present in tumor stroma. These actions raised the hypothesis that antibodies directed against the PD signaling axis (both anti-PD-L1 and anti-PD) might be useful in cancer treatment by allowing reactivation of the immune response against tumors. Indeed, nivolumab and lambrolizumab, both anti-PD antibodies, have shown evidence of important immune-mediated actions against certain solid tumors, including melanoma and lung cancers."
        },
        {
            "id": "InternalMed_Harrison_14813",
            "title": "InternalMed_Harrison",
            "content": "thymidine analogue) rather than its antiviral effects. LSG15, a multidrug chemotherapy program developed in Japan, induces complete responses in about one-third of patients, about half of whom survive more than 2 years; however, but the median survival time is about 13 months. A pilot trial suggested that mogamulizumab, an antibody to CCR4 (a receptor for a number of chemokines, including RANTES and TARC), improved response rates when added to chemotherapy. An experimental approach using an yttrium 90\u2013labeled or toxin-conjugated antibody to the IL-2 receptor appears promising but is not widely available. Patients with the chronic or smoldering form of ATL may be managed with an expectant approach: treat any infections, and watch and wait for signs of progression to acute disease."
        },
        {
            "id": "InternalMed_Harrison_6406",
            "title": "InternalMed_Harrison",
            "content": "The anti-VEGF antibody bevacizumab shows little evidence of antitumor effect when used alone, but when combined with chemotherapeutic agents, it improves the magnitude of tumor shrinkage and time to disease progression in colorectal and nonsquamous lung cancers. The mechanism for the effect is unclear and may relate to the capacity of the antibody to alter delivery and tumor uptake of the active chemotherapeutic agent. Ziv-aflibercept is not an antibody, but a solubilized VEGF receptor VEGF binding domain, and therefore may have a distinct mechanism of action with comparable side effects."
        },
        {
            "id": "Surgery_Schwartz_8947",
            "title": "Surgery_Schwartz",
            "content": "as important in LPS recognition, resulting in the release of inflammatory cytokines and mediators. Studies have shown that although LBP is important, it is not required for LPS to interact with CD14; however, its presence markedly decreases the concentration of LPS necessary for cellular acti-vation. This may be important especially at the low concentra-tions of LPS found under physiological conditions. CD14 exists in two forms, membrane (mCD14) and soluble (sCD14) form. The interaction of LPS with membrane CD14 or soluble CD14 is important in host clearance of LPS. This interaction is also responsible for the toxic effects of LPS seen in the liver and systemic circulation after the release of inflammatory cytokines and mediators. While membrane CD14 is a membrane protein found on the surface of myeloid lineage and mediates the activa-tion of these cells by LPS, soluble CD14 is found in the serum and enables responses to LPS by cells that do not express CD14. In addition to its"
        },
        {
            "id": "Pharmacology_Katzung_5978",
            "title": "Pharmacology_Katzung",
            "content": "Panitumumab is a fully human monoclonal antibody directed against the EGFR and works through inhibition of the EGFR signaling pathway. In contrast to cetuximab, this antibody is of the G2 isotype and, as such, would not be expected to exert any immunologic-mediated effects. Panitumumab was originally approved for patients with refractory metastatic CRC who have been treated with all other active agents. However, it is now also approved for use in combination with FOLFOX chemotherapy in the front-line treatment of metastatic CRC. As with cetuximab, this antibody is only effective in patients whose tumors express wild-type RAS. Recent clinical studies have shown that this antibody can also be effectively and safely combined with irinotecanbased chemotherapy in the second-line treatment of metastatic CRC. Acneiform skin rash and hypomagnesemia are the two main adverse effects associated with its use. Despite being a fully human antibody, infusion-related reactions can still be observed,"
        },
        {
            "id": "Immunology_Janeway_4130",
            "title": "Immunology_Janeway",
            "content": "Herceptin is thought to act by blocking the binding of the natural ligand (so far unidentified) to this receptor, and by downregulating the level of expression of the receptor. The effects of this antibody can be enhanced when it is combined with conventional chemotherapy. Beyond blocking a growth signal for tumor cells, experiments in mice suggest that some of trastuzumab\u2019s antitumor effects also involve innate and adaptive immune responses, such as directing ADCC or inducing antitumor T-cell responses. A monoclonal antibody that has yielded excellent results in the treatment of non-Hodgkin\u2019s B-cell lymphoma is the anti-CD20 antibody rituximab, which triggers the apoptosis of B cells upon binding to CD20 on their surface (see Section 16-7). ADCC may be another mechanism by which rituximab acts, as its clinical efficacy has been linked to polymorphisms in activating Fc receptors."
        },
        {
            "id": "InternalMed_Harrison_8541",
            "title": "InternalMed_Harrison",
            "content": "cell proliferation (e.g., farnesyl transferase inhibitors), protein synthesis (e.g., aminopeptide inhibitors) and folding (e.g., heat shock protein inhibitors), and ubiquitination, or with novel cytotoxic mechanisms (e.g., clofarabine, sapacitabine), are being tested in clinical trials. Furthermore, approaches with antibodies targeting commonly expressed leukemia blasts (e.g., CD33) or leukemia initiating cells (e.g., CD123) and immunomodulatory agents (e.g., lenalidomide) are also under investigation. Once these compounds have demonstrated safety and activity as single agents, investigation of combinations with other molecular targeting compounds and/or chemotherapy should be pursued."
        },
        {
            "id": "Immunology_Janeway_4074",
            "title": "Immunology_Janeway",
            "content": "Fig. 16.10 Treatment with an anti-\u03b14 integrin humanized monoclonal antibody reduces relapses in multiple sclerosis. Left panel: interaction between \u03b14:\u03b21 integrin (VLA-4) on lymphocytes and macrophages and VCAM-1 expressed on endothelial cells permits the adhesion of these cells to brain endothelium. This facilitates the migration of these cells into the plaques of inflammation in multiple sclerosis. Center panel: the monoclonal antibody natalizumab (blue) binds to the \u03b14 chain of the integrin and blocks adhesive interactions between lymphocytes and monocytes and VCAM-1 on endothelial cells, thus preventing the cells from entering the tissue and exacerbating the inflammation. The future of this treatment is unclear because of the development of a rare infection as a side-effect (see the text). Right panel: the number of new lesions detected on magnetic resonance imaging (MRI) of the brain is greatly reduced in patients treated with natalizumab compared with a placebo. Data from"
        },
        {
            "id": "Pharmacology_Katzung_6161",
            "title": "Pharmacology_Katzung",
            "content": "Catumaxomab is a recombinant bi-specific trifunctional rat-mouse IgG hybrid monoclonal antibody that targets the epithelial cell adhesion molecule (EpCAM) on tumor cells and the CD3 protein on T cells. This bi-specific monoclonal antibody is approved in the USA and EU as an orphan drug for treating abdominal ascites in ovarian and gastric cancers. The rationale behind the bi-specific characteristics of catumaxomab is that it brings CD3-expressing anti-tumor T cells into close proximity of tumor cells expressing EpCAM. The Fc portion of the antibody also recruits phagocytic cells that mediate antibody-dependent cellular cytotoxicity and complement, resulting in complement-dependent cytotoxicity of tumor cells."
        },
        {
            "id": "Immunology_Janeway_4068",
            "title": "Immunology_Janeway",
            "content": "and into the gut wall in Crohn\u2019s disease. However, blockade of \u03b14:\u03b21 integrin is not specific and, like anti-TNF therapy, could lead to reduced defense against infection. Rarely patients treated with natalizumab have developed progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus. This led to the temporary withdrawal of natalizumab from the market in 2005, but in June 2006 it was again allowed to be prescribed for multiple sclerosis and for Crohn\u2019s disease."
        },
        {
            "id": "Pharmacology_Katzung_6980",
            "title": "Pharmacology_Katzung",
            "content": "Integrins are a family of adhesion molecules on the surface of leukocytes that may interact with another class of adhesion molecules on the surface of the vascular endothelium known as selectins, allowing circulating leukocytes to adhere to the vascular endothelium and subsequently move through the vessel wall into the tissue. Integrins consist of heterodimers that contain two subunits, alpha and beta. Two monoclonal antibodies directed against integrins are available for the treatment of inflammatory bowel disease: natalizumab and vedolizumab. Both are administered intravenously. Natalizumab is a humanized IgG4 monoclonal antibody targeted only against the \u03b14 subunit; thus, it blocks several integrins on circulating inflammatory cells and prevents binding to the vascular adhesion molecules and subsequent migration into surrounding tissues, including the bowel and central nervous system. Unfortunately, patients treated with natalizumab may develop progressive multifocal"
        },
        {
            "id": "Immunology_Janeway_4267",
            "title": "Immunology_Janeway",
            "content": "16-17 Monoclonal antibodies against tumor antigens, alone or linked to toxins, can control tumor growth. Bradley,A.M., Devine, M., and DeRemer, D.: Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. Am. J. Health Syst. Pharm. 2013, 70:589\u2013597. Hortobagyi, G.N.: Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 2005, 353:1734\u20131736. Kreitman, R.J., Wilson, W.H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D.J., and Pastan, I.: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 2001, 345:241\u2013247. Park, S., Jiang, Z., Mortenson, E.D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N.K., Greene, M., et al.: The therapeutic effect of antiHER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18:160\u2013170."
        },
        {
            "id": "InternalMed_Harrison_407",
            "title": "InternalMed_Harrison",
            "content": "in remarkable antitumor efficacy. Similarly, the anti\u2013epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab appear especially effective in colon cancers in which K-ras, a G protein in the EGFR pathway, is not mutated. Vemurafenib does not inhibit wild-type BRAF but is active against the V600E mutant form of the kinase."
        },
        {
            "id": "InternalMed_Harrison_7035",
            "title": "InternalMed_Harrison",
            "content": "both cetuximab and panitumumab can lead to an acne-like rash, with the development and severity of the rash being correlated with the likelihood of antitumor efficacy. Inhibitors of the EGFR tyrosine kinase such as erlotinib (Tarceva) or sunitinib (Sutent) do not appear to be effective in colorectal cancer."
        },
        {
            "id": "InternalMed_Harrison_9560",
            "title": "InternalMed_Harrison",
            "content": "interaction of LPS from gram-negative bacteria and the GPI-anchored membrane protein CD14 found on the surface of professional phagocytes, including migrating and tissue-fixed macrophages and PMNs. A soluble form of CD14 is also found in plasma and on mucosal surfaces. A plasma protein, LPS-binding protein, transfers LPS to membrane-bound CD14 on myeloid cells and promotes binding of LPS to soluble CD14. Soluble CD14/LPS/LPS-binding protein complexes bind to many cell types and may be internalized to initiate cellular responses to microbial pathogens. It has been shown that peptidoglycan and lipoteichoic acid from gram-positive bacteria as well as cell-surface products of mycobacteria and spirochetes can interact with CD14 (Fig. 145e-3). Additional molecules, such as MD-2, also participate in the recognition of bacterial activators of inflammation."
        },
        {
            "id": "InternalMed_Harrison_6405",
            "title": "InternalMed_Harrison",
            "content": "EGF receptor (EGFR)-directed antibodies (such as cetuximab and panitumumab) have activity in colorectal cancer refractory to chemotherapy, particularly when used to augment the activity of an additional chemotherapy program, and in the primary treatment of head and neck cancers treated with radiation therapy. The mechanism of action is unclear. Direct effects on the tumor may mediate an antiproliferative effect as well as stimulate the participation of host mechanisms involving immune cell or complement-mediated response to tumor cell\u2013bound antibody. Alternatively, the antibody may alter the release of paracrine factors promoting tumor cell survival."
        },
        {
            "id": "Pharmacology_Katzung_6182",
            "title": "Pharmacology_Katzung",
            "content": "Reslizumab binds and neutralizes the biological activity of IL-5, thereby suppressing the production and survival of eosinophils. It is approved for adult patients with severe eosinophilic asthma. Mepolizumab also binds to IL-5 and selectively inhibits eosinophilic inflammation in patients with severe eosinophilic asthma. Siltuximab is a Mab that binds to and blocks IL-6 from binding to its cellular receptor. It is approved for the treatment of patients with multicentric Castleman\u2019s disease who are HIV-negative and HHV-8-negative. Tocilizumab is recombinant humanized IgG1 that binds to soluble and membrane-associated IL-6 receptors. It inhibits IL-6-mediated signaling on lymphocytes, suppressing inflammatory processes. Similar to anti-TNF-\u03b1 Mabs, patients receiving tocilizumab should be closely monitored for infectious diseases such as tuberculosis and other invasive bacterial, fungal, and viral infections."
        },
        {
            "id": "InternalMed_Harrison_6167",
            "title": "InternalMed_Harrison",
            "content": "Preclinical studies targeting death receptors DR4 and DR5 have demonstrated that recombinant, soluble, human TRAIL or humanized monoclonal antibodies with agonist activity against DR4 or DR5 can induce apoptosis of tumor cells while sparing normal cells. The mechanisms for this selectivity may include expression of decoy receptors or elevated levels of intracellular inhibitors (such as FLIP, which competes with caspase-8 for FADD) by normal cells but not tumor cells. Synergy has been shown between TRAIL-induced apoptosis and chemotherapeutic agents. For instance, some colon cancers encode mutated Bax protein as a result of mismatch repair (MMR) defects and are resistant to TRAIL. However, upregulation of Bak by chemotherapy restores the ability of TRAIL to activate the mitochondrial pathway of apoptosis. However, clinical studies have not yet shown significant activity of approaches targeting the TRAIL pathway."
        },
        {
            "id": "Pharmacology_Katzung_4566",
            "title": "Pharmacology_Katzung",
            "content": "Danazol, an isoxazole derivative of ethisterone (17\u03b1-ethinyltestosterone) with weak progestational, androgenic, and glucocorticoid activities, is used to suppress ovarian function. Danazol inhibits the midcycle surge of LH and FSH and can prevent the compensatory increase in LH and FSH following castration in animals, but it does not significantly lower or suppress basal LH or FSH levels in normal women (Figure 40\u20135). Danazol binds to androgen, progesterone, and glucocorticoid receptors and can translocate the androgen receptor into the nucleus to initiate androgen-specific RNA synthesis. It does not bind to intracellular estrogen receptors, but it does bind to sex hormone\u2013 binding and corticosteroid-binding globulins. It inhibits P450scc (the cholesterol side chain\u2013cleaving enzyme), 3\u03b2-hydroxysteroid dehydrogenase, 17\u03b1-hydroxysteroid dehydrogenase, P450c17 (17\u03b1-hydroxylase), P450c11 (11\u03b2-hydroxylase), and P450c21 (21\u03b2-hydroxylase). However, it does not inhibit aromatase, the enzyme"
        },
        {
            "id": "Pharmacology_Katzung_6164",
            "title": "Pharmacology_Katzung",
            "content": "Dinutuximab is a ganglioside D2 (GD2)-binding Mab approved for pediatric patients with high-risk neuroblastoma in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA) who achieve at least a partial response to prior first-line multiagent, multimodality therapy. It has a black box warning for serious infusion reactions and neurotoxicity in the majority of patients. Necitumumab is a Mab directed against epidermal growth factor receptor (EGFR) and approved for use in patients with squamous non-small cell lung cancer in combination with gemcitabine and cisplatin. There is a black box warning for cardiopulmonary arrest and hypomagnesemia."
        },
        {
            "id": "Pharmacology_Katzung_3985",
            "title": "Pharmacology_Katzung",
            "content": "Most patients respond to abatacept within 12\u201316 weeks after the initiation of the treatment; however, some patients can respond in as few as 2\u20134 weeks. A study showed equivalence between adalimumab (see TNF-\u03b1 Blocking Agents) and abatacept. 3."
        }
    ],
    "scores": [
        0.026575601088344718,
        0.02480501221750139,
        0.020964635854341735,
        0.01995173048576131,
        0.01913919413919414,
        0.01846494213750851,
        0.01746031746031746,
        0.017324133793310333,
        0.015891811043250655,
        0.01582751744765703,
        0.015274599542334096,
        0.015142857142857142,
        0.014946182588812671,
        0.01466795615731786,
        0.014445139758030872,
        0.014407131011608624,
        0.014046855254204335,
        0.013944034789185102,
        0.013651108307803209,
        0.013355521420037549,
        0.013013901212658975,
        0.012307459981878587,
        0.012014720738923367,
        0.011655405405405406,
        0.011500330469266358,
        0.011038529002600859,
        0.010924095348353964,
        0.010341510341510343,
        0.010235602094240837,
        0.009900990099009901,
        0.009900990099009901,
        0.009900990099009901
    ]
}